Phase II Study of Prolonged Oral VP-16 for Advanced Ovarian Epithelial and Cervical Cancer

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed recurrent or metastatic ovarian
epithelial or cervical cancer Tissue not accessible for biopsy Refractory to curative
therapy or established treatments and ineligible for higher priority GOG protocols
Measurable disease required, as follows: Lesion measurable by physical exam Lesion
bidimensionally measurable on sonogram or imaging Ascites/pleural effusion not measurable

PATIENT CHARACTERISTICS: Age: Any age Performance status: GOG 0-2 Hematopoietic: WBC at
least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelets at least
100,000/mm3 Hepatic: Bilirubin no more than 1.5 times normal AST no more than 3 times
normal Alkaline phosphatase no more than 3 times normal Renal: Creatinine no greater than
2.0 mg/dL Other: Body surface area at least 1 square meter No requirement for intravenous
hydration or nutritional support No significant infection No second malignancy other than
nonmelanomatous skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since anticancer therapy
Chemotherapy: No more than 1 prior chemotherapy trial No prior etoposide At least 3 weeks
since chemotherapy and recovered Endocrine therapy: At least 3 weeks since anticancer
therapy Radiotherapy: At least 3 weeks since radiotherapy Surgery: At least 3 weeks since
surgery and recovered